Alzheimer's Test Predicts Cognitive Decline in Parkinson's

Kate H. Gamble, Senior Editor
Published Online: Thursday, December 22, 2011
Follow Pharmacy_Times:
A method of classifying brain atrophy patterns in Alzheimer’s disease patients using MRIs can also detect cognitive decline in Parkinson’s disease, according to a new study published in Brain.

Researchers from the Perelman School of Medicine at the University of Pennsylvania also found that higher baseline Alzheimer’s patterns of atrophy predicted long-term cognitive decline in cognitively normal Parkinson’s patients.

“On the basis of a simple neuroimaging study, we can now predict which patients with Parkinson’s disease will experience long-term cognitive decline or develop dementia in the future,” said the study’s lead author, Daniel Weintraub, MD, in a statement. “Diagnostic tests like this can help us determine which patients would benefit from future clinical trials of medications aiming to stave off or prevent dementia progression in Parkinson’s disease.”

This research raises the possibility that both Alzheimer’s disease and Parkinson’s disease pathology contribute to cognitive decline in Parkinson’s disease. Researchers are still uncertain whether the neurodegeneration seen in these patients is caused by primary Parkinson’s disease pathology, Alzheimer’s pathology, a combination of the two, or is a form of compensation.

As biomarkers for Alzheimer’s and Parkinson’s disease continue to emerge, the researchers suggest at least an overlap in regions undergoing neurodegeneration with cognitive decline, and point to the Spatial Pattern of Abnormalities for Recognition of Alzheimer’s disease (SPARE-AD) classification system to detect brain atrophy in Parkinson’s disease, to detect patients at imminent risk of cognitive decline before clinically identifiable symptoms emerge.

Approximately 80% of Parkinson’s patients become demented over the course of the illness. Some patients experience cognitive impairment relatively soon after the disease presents, while others won’t experience dementia until the very end of their disease. Duration and severity of the disease and advanced age are risk factors for dementia, while nearly 20% of patients never have dementia. More than half of Parkinson’s patients with dementia have significant signs of Alzheimer’s disease-related plaques and neurofribrillary tangles on autopsy, and similar brain regions, such as the hippocampus and medial temporal lobe, have been reported to be affected in both diseases.

The Penn research team applied a pattern classification individual-based score, the SPARE-AD score, to a cross-sectional cohort of 84 Parkinson’s patients including patients with dementia, mild cognitive impairment and no dementia. In the cross-sectional analyses, the SPARE-AD score correlated to cognitive impairment across all groups. From this group, 59 Parkinson’s patients without dementia were followed for an additional two years. Researchers determined that a higher baseline SPARE-AD score predicted worsening cognitive performance over time, even in those patients with normal cognition at baseline.

Related Articles
The University of Mississippi School of Pharmacy will be installing 3 new nuclear magnetic resonance (NMR) spectrometers that aid in drug discovery.
A pharmacist in Cleveland, Tennessee, has surrendered her license following an investigation into her compounding pharmacy’s use of potentially unsafe ingredients.
Students in Long Island, New York, interested in pursuing a pharmacy degree may soon have a nearby option for pharmacy school.
Students who have not yet obtained a bachelor’s degree can now apply to the Cedarville University School of Pharmacy.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$